SIGA Technologies

SIGA Technologies' mission is to protect humanity against severe infectious diseases by developing and commercializing critical medical countermeasures. Its core achievement is the successful development and regulatory approval of TPOXX® (tecovirimat), the first oral antiviral for smallpox, which forms the cornerstone of a durable, government-focused revenue stream. The company's strategy is to deepen its role as an essential biodefense partner to the U.S. and allied governments while expanding TPOXX's label into new indications like post-exposure prophylaxis and pediatric use, thereby solidifying its market leadership in the orthopoxvirus space.

Structure-based small-molecule antiviral discovery platform with deep expertise in orthopoxvirus biology, focused on inhibiting essential viral proteins like VP37 to prevent viral spread.

Effectively holds a monopoly following Chimerix's exit from the market. Competition is limited to early-stage vaccine developers and government/academic research, none of which offer a directly competing, approved therapeutic. High regulatory and relationship barriers protect SIGA's position.